Company: AZN
Filing Date: 2025-07-22
Form Type: 6-K
Source: 0001654954-25-008260
Chunk: 2

Company: ASTRAZENECA PLC
Filing Date: 2025-07-22
Form: 6-K
Chunk 2
---
, Chief Executive Officer, AstraZeneca, said: "Today's announcement underpins our belief in America's innovation in biopharmaceuticals and our commitment to the millions of patients who need our medicines in America and globally. It will also support our ambition to reach $80 billion in revenue by 2030. I look forward to partnering with Governor Youngkin and his team to work on our largest single manufacturing investment ever. It reflects the Commonwealth of Virginia's desire to create highly skilled jobs in science and technology, and will strengthen the country's domestic supply chain for medicines."

#### Notes

#### AstraZeneca in the US
The US is AstraZeneca's largest market and home to 19 R&D, manufacturing and commercial sites. We employ more than 18,000 people and support 92,000 jobs overall across the United States. In 2024 we contributed $5 billion directly to the economy and created approximately $20 billion worth of overall value for the American economy.

Today the US represents 42% of our Total Revenue with an ambition to reach 50% by 2030. This underscores the critical role the US plays in our ability to deliver on our ambition to launch 20 new medicines by the end of the decade.

#### AstraZeneca
AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca's innovative medicines are sold in more than 125 countries and used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on social media @AstraZeneca .

#### Contacts
For details on how to contact the Investor Relations Team, please click here . For Media contacts, click here .

#### Matthew Bowden

#### Company Secretary

#### AstraZeneca PLC
<div align='center'>SIGNATURES</div>

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

| AstraZeneca 
 PLC         |

Date:22 July 2025

| By: /s/           
 Adrian Kemp       |
| Name:             
 Adrian Kemp       |
|